Clinical-stage, small molecule biotechnology company Redx Pharma (JPJ: REDX) announced on Monday that it presented positive Phase 1 trial results for RXC008, a potential first-in-class treatment for fibrostenotic Crohn's disease, at the 20th Congress of the European Crohn's and Colitis Organisation in Berlin.
RXC008, an orally administered pan-ROCK inhibitor designed to remain gut-restricted, was well tolerated across all tested doses, with no safety concerns, serious adverse events, or discontinuations.
The study confirmed that RXC008 achieved predicted efficacious concentrations in gastrointestinal tissue with minimal systemic exposure, avoiding cardiovascular side effects associated with systemic pan-ROCK inhibitors.
A Phase 2 trial is planned for H2 2025.
Redx Pharma focuses on developing targeted small-molecule therapeutics for fibrotic diseases and oncology, with an industry-leading ROCK inhibitor portfolio.
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Innovent Biologics doses first patient in registrational study assessing IBI363
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
AstraZeneca's camizestrant shows significant PFS benefit in HR+ breast cancer
FDA accepts Telix Pharmaceuticals' BLA for Zircaix and grants Priority Review
Summit Therapeutics and Pfizer partner to evaluate ivonescimab with ADCs in solid tumor trials
Bristol Myers Squibb's application for Opdivo-Yervoy combo in colorectal cancer accepted by U.S. FDA
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Sectra and Siemens Healthineers collaborate to enhance radiology diagnostics
ValiRx Plc concludes evaluation project with Imperial College London